Your session is about to expire
← Back to Search
Monoclonal Antibodies
MT10109L Dose 2/Dose 1+2 for Frown Lines
Phase 3
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 720
Awards & highlights
Study Summary
This trial is looking at the safety of MT10109L in the treatment of moderate to severe GL and/or LCL.
Eligible Conditions
- Frown Lines
- Crow's Feet
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 720
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 720
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean change from baseline in blood pressure (mm Hg)
Mean change from baseline in pulse rate (beats per minute)
Mean change from baseline in respiratory rate (breaths per minute)
+2 moreTrial Design
8Treatment groups
Experimental Treatment
Group I: Placebo/MT10109L Dose 2Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-002 lead-in study, who received Placebo in period 1 and MT10109L Dose 2 in period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
Group II: Placebo/MT10109L Dose 1 + Dose 2Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-005 and MT10109L-006 lead-in studies, who received Placebo in periods 1 & 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
Group III: Placebo/MT10109L Dose 1Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-001 lead-in study, who received Placebo in period 1 and MT10109L Dose 1 in period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study
Group IV: MT10109L Dose 2/Dose 2Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-002 lead-in study, who received MT10109L Dose 2 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
Group V: MT10109L Dose 2/Dose 1+2Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-006 lead-in study, who received MT10109L Dose 2 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
Group VI: MT10109L Dose 1/Dose 1+2Experimental Treatment1 Intervention
The participant pool in this arm are from the from MT10109L-005 lead-in study, who received MT10109L Dose 1 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
Group VII: MT10109L Dose 1/Dose 1Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-001 lead-in study, who received MT10109L Dose 1 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study.
Group VIII: MT10109L Dose 1+2/Dose 1+2Experimental Treatment1 Intervention
The participant pool in this arm are from the MT10109L-005 and MT10109L-006 lead-in studies, who received MT10109L Dose 1 into GL and Dose 2 into LCL in periods 1 & 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MT10109L Dose 1 + Dose 2
2019
Completed Phase 3
~960
MT10109L Dose 1
2019
Completed Phase 3
~960
MT10109L Dose 2
2019
Completed Phase 3
~960
Find a Location
Who is running the clinical trial?
AllerganLead Sponsor
781 Previous Clinical Trials
275,612 Total Patients Enrolled
1 Trials studying Frown Lines
101 Patients Enrolled for Frown Lines
Medy-ToxLead Sponsor
51 Previous Clinical Trials
7,720 Total Patients Enrolled
ALLERGAN INC.Study DirectorAllergan
75 Previous Clinical Trials
78,302 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
At how many hospitals is this treatment being tested?
"Presently, this clinical trial is enrolling patients from 26 different sites. While some of these locations are in Bradenton, Scottsdale and Wilmington, there are also 23 other medical centres where you may be able to enroll. If you choose to participate in this study, it would be most convenient for you to select a location closest to your home to avoid excessive travel."
Answered by AI
Does MT10109L have the thumbs up from the FDA?
"MT10109L's position on the Power safety scale is a 3. This is due to it being a Phase 3 trial, which implies that not only does some data support efficacy, but multiple rounds of data also support safety."
Answered by AI
Are we currently signing people up for this experiment?
"According to the listing on clinicaltrials.gov, this trial has stopped recruiting patients as of 7/15/2022. The study was originally posted on 10/23/2019. Although this particular trial is no longer searching for candidates, there are 7 other active studies that might be a match for you."
Answered by AI
Who else is applying?
What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
DermResearch Inc. /ID# 232727
DermResearch Inc.
Sweat Clinics of Canada
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger